I wish we had filled the gap at $1.6 so we could put a stop to...

I wish we had filled the gap at $1.6 so we could put a stop to such discussions. Well we hit close enough and bounced off from $1.615. As a lay man I think today’s price action held up well despite 500k shares changing hands.

No matter what people think, IMHO very few companies would take the onslaught Race has endured in the last year simply because of the fundamentals and mgmt and BOD actions. If not for that we would probably not have crossed 50c in the first place. So as long as the FA is strong (hoping for great Melanoma results) whether we close a gap $1.6 or other price points is pointless IMO. We also have to survive the tax loss selling until June-end.

All we need is for Zantrene to be effective and safe in one cancer in a phase 2 trial, that is all required to be undervalued. Whether LT we get acquired for $XX Bn is a discussion for down the track.